Coronaviruses are a large group of viruses that can cause a range of diseases from the common cold to more serious respiratory infections such as bronchitis, pneumonia or severe acute respiratory syndrome (SARS). In rare cases, animal coronaviruses can infect humans, and even more rarely, these coronaviruses can be transmitted from person to person through close contact, such as in a household or workplace.
BOC Sciences provides specialized libraries of screening compounds for different anti-coronavirus drug discovery studies, they are 2019-nCoV main protease targeted library, eEF1A target library, 2019-nCoV papain-like protease targeted library, SARS coronavirus focused library.
Figure 1. Three-dimensional structures of (A) SARS-CoV Mpro, (B) SARS-CoV-2 Mpro, (C) SARS-CoV PLpro, (D) SARS-CoV-2 PLpro. (Saa, A.; et al. 2020)
Coronavirus Screening Library Design
A newly emerged 2019 highly infectious novel coronavirus disease 2019 (COVID-19) has been identified in humans, and it is named as severe acute respiratory syndrome (SARS)-CoV-2 (SARS-CoV-2). Scientists identify natural phytochemicals from medicinal plants in order to repurpose them against COVID-19 through molecular docking and molecular dynamics (MD) simulation studies. BOC Sciences is focused on designing a library to synthesize diverse anti-SARS-CoV-2 M inhibitors
Based on recent studies related to the COVID-19 therapy, it has been suggested that human elongation factor 1-alpha (eEF1A) may be a promising anti-coronavirus drug target. eEF1A is an essential and highly methylated protein that promotes translational elongation by delivering aminoacyl-tRNA to the ribosome. Our scientists are committed to designing an eEF1A targeted library, and are able to select nearly 3,000 promising ligands that have high predicted affinity for eEF1A
The outbreak of virus containing a single positive-stranded RNA first identified to have occurred in Wuhan, China and was named severe acute respiratory syndrome (SARS)-CoV-2 (SARS-CoV-2). The impact of the current COVID-19 outbreak and the possibility of an impending CoV epidemic demonstrate the need for rapid discovery of anti-COVID-19 drugs. Viral proteases are key targets for drug discovery, and scientists are paying close attention to two viral proteases: main protease (Mpro) and papain-like protease (PLpro), as they are essential for viral replication
SARS virus belongs to the coronavirus family, the virus particles are mostly round, with a capsule membrane, the periphery has a coronal arrangement of cilia. SARS virus is distributed in the cell pulp, and in a round shape. The diameter of the virus is generally between 80-120 nm. SARS is an infectious disease with rapid onset, rapid transmission and high mortality rate. BOC Sciences has employed a 2D fingerprints similarity search approach for screening of a reference set of compounds known to be active against SARS coronavirus
Figure 2. Targeting SARS-CoV-2 proteases. ( Steuten, K.; et al. 2021)
Coronavirus Screening Library Characteristics
- Bioactivity and safety confirmed by preclinical studies and clinical trials
- Structural diversity, medicinal activity, and cellular penetration
- Structural document, IC50, and other chemical and biological data are provided
- All compounds are continually updated
- Compound cherry-picking service is provided
What We Deliver
- Delivered within 2 weeks in any customer-preferred format
- Powders, dry films or DMSO solutions formatted in vials, 96 or 384-well plates
- All compounds have a minimum purity of 90% assessed by 1H NMR and HPLC
- Analytical data is provided
BOC Sciences provides professional, rapid and high-quality services of Coronavirus Screening Library design at competitive prices for global customers. Personalized and customized services of Coronavirus Screening Library design can satisfy any innovative scientific study demands. Our clients have direct access to our staff and prompt feedback to their inquiries. If you are interested in our services, please contact us immediately!
References
- Saa, A.; et al. Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors. Bioorganic & Medicinal Chemistry. 2020. 29.
- Steuten, K.; et al. Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19. Europe PMC. 2021. 7(6): 1457-1468.
